Epidemic Bacillus endophthalmitis after cataract surgery I: acute presentation and outcome.
OBJECTIVE
The purpose of the study is to report the clinical outcome of acute Bacillus endophthalmitis after cataract surgery.


METHODS
The study design is a cohort study.


METHODS
Fourteen eyes of 14 patients with epidemic acute postoperative inflammation after exposure to bacteria-contaminated viscoelastic material were studied.


METHODS
Three patients with milder clinical presentations were treated without vitrectomy or antibiotics. Eleven patients with more severe infection were treated with vitrectomy as well as intravitreous and topical fortified antibiotics.


METHODS
Final visual acuities were obtained in all 14 study patients. Results of microbiologic studies of aqueous and vitreous specimens from 11 vitrectomized eyes also were analyzed.


RESULTS
One patient with late presentation had severe inflammation and had phthisis bulbi develop with no light perception. The remaining 13 patients had successful resolution of inflammation after treatment by 1 month of follow-up. Twelve of these 13 patients, including 1 nonvitrectomized patient, had final visual acuities of 20/100 or better at 6 months' follow-up. Six patients, including two patients with nonvitrectomized eyes, had outcomes of 20/40 or better visual acuity. Bacillus species were grown from all 11 (100%) vitreous and 7 (88%) of 8 aqueous specimens obtained from vitrectomized patients, as well as from the contaminated viscoelastic material remaining in the operating room.


CONCLUSIONS
Postoperative Bacillus endophthalmitis need not result in poor outcome. Results depend on factors including bacterial load, specific bacterial species, timing of treatment, and immune status of the patient.
Roy
M
M
Department of Ophthalmology, McGill University, Montreal, Canada.
Chen
J C
JC
Miller
M
M
Boyaner
D
D
Kasner
O
O
Edelstein
E
E
D000208:Acute Disease; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents; D001082:Aqueous Humor / Q000382:microbiology; D016863:Bacillaceae Infections / Q000209:etiology* / Q000628:therapy; D001407:Bacillus / Q000302:isolation & purification*; D002387:Cataract Extraction / Q000009:adverse effects*; D015331:Cohort Studies; D004340:Drug Contamination; D004359:Drug Therapy, Combination / Q000627:therapeutic use; D009877:Endophthalmitis / Q000382:microbiology* / Q000628:therapy; D015818:Eye Infections, Bacterial / Q000209:etiology* / Q000628:therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006820:Hyaluronic Acid; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000382:microbiology* / Q000628:therapy; D016896:Treatment Outcome; D014792:Visual Acuity; D014821:Vitrectomy; D014822:Vitreous Body / Q000382:microbiology
D000900:Anti-Bacterial Agents; D006820:Hyaluronic Acid